AMEX
0.25USD
+0.01 (+2.14%)
We have scored 5 news catalysts on IGC Pharma, Inc. (IGC) over the past 12 months. The biggest single-day move next to one of them came Dec 19, 2025, when IGC closed −10.7%: “IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum”. Coverage across the window leans positive (average ticker sentiment +0.70). Most of the impact sits in price momentum and sector healthcare.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
25.6M
P/E
—
EPS
—
Beta
0.48
52W range
0.235-0.4508
Day range
0.24–0.25
Open
0.24
Prev close
0.24
Volume
176.2K
Avg volume
658.8K
Dividend
0.00
IPO
2006-05-24
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about IGC Pharma, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for IGC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
